For those desiring to outshine the market, the strategic selection of individual stocks is paramount. Well-chosen stocks have the potential to substantially boost your wealth.
As of close of business last night, Beam Therapeutics Inc’s stock clocked out at $19.12, up 1.54% from its previous closing price of $18.83. In other words, the price has increased by $1.54 from its previous closing price. On the day, 1.59 million shares were traded. BEAM stock price reached its highest trading level at $19.425 during the session, while it also had its lowest trading level at $18.53.
Ratios:
To gain a deeper understanding of BEAM’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 8.81 and its Current Ratio is at 8.81. In the meantime, Its Debt-to-Equity ratio is 0.14 whereas as Long-Term Debt/Eq ratio is at 0.13.
On March 10, 2025, Scotiabank Upgraded its rating to Sector Outperform which previously was Sector Perform but kept the price unchanged to $40.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Jul 30 ’25 when FMR LLC sold 48,374 shares for $20.50 per share. The transaction valued at 991,667 led to the insider holds 2,073,665 shares of the business.
Simon Amy sold 876 shares of BEAM for $17,625 on Jul 03 ’25. The Chief Medical Officer now owns 64,864 shares after completing the transaction at $20.12 per share. On Jul 01 ’25, another insider, Simon Amy, who serves as the Chief Medical Officer of the company, sold 374 shares for $16.94 each. As a result, the insider received 6,336 and left with 65,740 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, BEAM now has a Market Capitalization of 1922649984 and an Enterprise Value of 802113344. For the stock, the TTM Price-to-Sale (P/S) ratio is 30.24 while its Price-to-Book (P/B) ratio in mrq is 1.71. Its current Enterprise Value per Revenue stands at 12.616 whereas that against EBITDA is -1.963.
Stock Price History:
The Beta on a monthly basis for BEAM is 2.16, which has changed by -0.25078368 over the last 52 weeks, in comparison to a change of 0.20799685 over the same period for the S&P500. Over the past 52 weeks, BEAM has reached a high of $35.25, while it has fallen to a 52-week low of $13.52. The 50-Day Moving Average of the stock is 2.50%, while the 200-Day Moving Average is calculated to be -15.71%.
Shares Statistics:
It appears that BEAM traded 2.15M shares on average per day over the past three months and 2199970 shares per day over the past ten days. A total of 100.56M shares are outstanding, with a floating share count of 89.83M. Insiders hold about 10.71% of the company’s shares, while institutions hold 93.39% stake in the company. Shares short for BEAM as of 1752537600 were 23661756 with a Short Ratio of 11.01, compared to 1749772800 on 21731372. Therefore, it implies a Short% of Shares Outstanding of 23661756 and a Short% of Float of 26.459998000000002.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
